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2 	  
ABSTRACT 1	  
 2	  
Conventional methods for intraoperative histopathologic diagnosis are labor- and time-intensive 3	  
and may delay decision-making during brain tumor surgery. Stimulated Raman scattering (SRS) 4	  
microscopy, a label-free optical process, has been shown to rapidly detect brain tumor infiltration 5	  
in fresh, unprocessed human tissues. Previously, the execution of SRS microscopy in a clinical 6	  
setting has not been possible. We report the first demonstration of SRS microscopy in an 7	  
operating room using a portable fiber-laser-based microscope in unprocessed specimens from 8	  
101 neurosurgical patients. Additionally, we introduce an image-processing method, stimulated 9	  
Raman histology (SRH), which leverages SRS images to create virtual hematoxylin and eosin-10	  
stained slides, revealing essential diagnostic features. In a simulation of intraoperative pathologic 11	  
consultation in 30 patients, the concordance of SRH and conventional histology for predicting 12	  
diagnosis was nearly perfect (κ>0.89) and accuracy exceeded 92%. We also built and validated a 13	  
multilayer perceptron based on quantified SRH image attributes that predicts brain tumor 14	  
subtype with 90% accuracy. This study provides insight into how SRH can now be used to 15	  
improve the surgical care of brain tumor patients. 16	  
3 	  
INTRODUCTION 1	  
The optimal surgical management of brain tumors varies widely depending on histologic 2	  
subtype. Though some tumors of the central nervous system (CNS) have a distinct gross 3	  
appearance, others are difficult to differentiate. Consequently, the importance of intraoperative 4	  
histopathologic diagnosis in brain tumor surgery has been recognized for over 85 years1.  5	  
Existing intraoperative histologic techniques, including frozen sectioning and cytologic 6	  
preparations, require skilled technicians and clinicians working in surgical pathology laboratories 7	  
to produce and interpret slides2. However, the number of centers where brain tumor surgery is 8	  
performed exceeds the number of board-certified neuropathologists, eliminating the possibility 9	  
for expert intraoperative consultation in many cases. Even in the most advanced, well-staffed 10	  
hospitals, turnaround time for intraoperative pathology reporting may delay clinical decision-11	  
making during surgery, highlighting the need for an improved system for intraoperative 12	  
histopathology.  13	  
The ideal system for intraoperative histopathology would deliver rapid, standardized, and 14	  
accurate diagnostic images to assist in surgical decision-making. Improved access to 15	  
intraoperative histologic data would enable examination of clinically relevant histologic 16	  
variations within a tumor and the assessment of the resection cavity for residual tumor. In 17	  
addition, given that the percentage of tumor removed at the time of surgery is a major prognostic 18	  
factor for brain tumor patients3, intraoperative techniques to accurately identify residual tumor 19	  
are essential.   20	  
The development of stimulated Raman scattering (SRS) microscopy in 2008 created the 21	  
possibility of rapid, label-free, high-resolution microscopic imaging of unprocessed tissue 22	  
specimens4. While SRS has been shown to reveal key diagnostic histologic features in brain 23	  
4 	  
tumor specimens5-7, major technical hurdles have hindered its clinical translation. SRS 1	  
microscopy requires two laser pulse trains that are temporally overlapped by less than the pulse 2	  
duration (ie, <100fs) and spatially overlapped by less than the focal spot size (ie, <100nm). 3	  
Achieving these conditions typically requires free-space optics mounted on optical tables and 4	  
state-of-the-art, solid-state, continuously water-cooled lasers that are not suitable for use in a 5	  
clinical environment4.  6	  
However, leveraging advances in fiber-laser technology8, we have engineered a clinical 7	  
SRS microscope, allowing us to execute SRS microscopy in a patient care setting for the first 8	  
time. Light guiding by the optical core of the fiber and the novel polarization-maintaining (PM) 9	  
implementation of the laser source have enabled service-free operation in our operating room for 10	  
over a year. The system also includes improved noise cancellation electronics for the suppression 11	  
of high relative intensity noise, one of the major challenges of executing fiber-laser-based SRS 12	  
microscopy.  13	  
Using this novel system, we show that SRS microscopy can serve as an effective, 14	  
streamlined alternative to traditional histologic methods, eliminating the need to transfer 15	  
specimens out of the operating room to a pathology laboratory for sectioning, mounting, dyeing, 16	  
and interpretation.  Moreover, because tissue preparation for SRS microscopy is minimal, key 17	  
tissue architectural details commonly lost in smear preparations and cytologic features often 18	  
obscured in frozen sections are preserved. We also report a unique method for SRS image 19	  
processing that simulates hematoxylin and eosin (H&E) staining, called stimulated Raman 20	  
histology (SRH), which highlights key histoarchitectural features of brain tumors and enables 21	  
diagnosis in near-perfect agreement with conventional H&E-based techniques. Finally, we 22	  
demonstrate how a supervised machine learning approach, based on quantified SRH image 23	  
5 	  
attributes, effectively differentiates among diagnostic classes of brain tumors. Our study 1	  
demonstrates that SRH may provide an automated, standardized method for intraoperative 2	  
histopathology that can be leveraged to improve the surgical care of brain tumors in the future.  3	  
 4	  
RESULTS 5	  
Engineering a Clinical SRS Microscope 6	  
To eliminate reliance on optical hardware incompatible with the execution of SRS microscopy in 7	  
an operating room, we created a fully-integrated imaging system with 5 major components: 1) a 8	  
fiber-coupled microscope with a motorized stage; 2) a dual-wavelength fiber-laser module; 3) a 9	  
laser control module; 4) a microscope control module; and 5) a computer for image acquisition, 10	  
display, and processing. The entire system is mounted in a portable, self-contained clinical cart, 11	  
utilizes a standard wall plug, and does not require water-cooling (Fig. 1A).  12	  
The dual-wavelength fiber-laser is based on the fact that the difference frequency of the 13	  
two major fiber gain media, Erbium (Er) and Ytterbium (Yb), overlaps with the high 14	  
wavenumber region of Raman spectra.  As described by Freudiger et al.8, the two synchronized 15	  
narrow-band laser pulse-trains required for SRS imaging are generated by narrow-band filtering 16	  
of a broad-band super-continuum derived from a single fiber-oscillator and, subsequently, 17	  
amplification in the respective gain media (Fig. 1B).  18	  
 For clinical implementation, we developed an all-fiber system based on PM components, 19	  
which greatly improved stability over the previous non-PM system. The system described here 20	  
was stable throughout transcontinental shipping (from California to Michigan), and continuous, 21	  
service-free, long-term (>1 year) operation in a clinical environment, without the need for 22	  
realignment. To enable high-speed diagnostic-quality imaging (1Mpixel in 2sec) with a signal-23	  
6 	  
to-noise ratio comparable to what can be achieved with solid-state lasers, we scaled the laser 1	  
output power to approximately 120mW for the fixed wavelength 790nm pump beam and 2	  
approximately 150mW for the tunable Stokes beam over the entire tuning range from 1010nm to 3	  
1040nm at 40MHz repetition rate and 2ps transform-limited pulse duration. We also developed 4	  
fully custom laser controller electronics to tightly control the many settings of this multi-stage 5	  
laser system based on a micro-controller. Once assembled, we determined that the SRS 6	  
microscope had a lateral resolution of 360nm (full width of half maximum) and axial resolution 7	  
of 1.8µm (Fig. S1).  8	  
While development of an all-fiber system was necessary for clinical implementation of 9	  
SRS, relative intensity noise intrinsic to fiber lasers vastly degrades SRS image quality (Fig. 1C). 10	  
To improve image quality, we developed a noise-cancelation scheme based on auto-balanced 11	  
detection8, in which a portion of the laser beam is sampled to provide a measure of the laser 12	  
noise that can then be subtracted in real-time. Here we demonstrate that we can achieve ~25x 13	  
improvement in the signal-to-noise ratio in a clinical setting, without the need for adjustment, 14	  
which is essential for revealing microscopic tissue architecture (Fig. 1D).  15	  
 16	  
Processing of Clinical SRS Images 17	  
Histologic images of fresh, unstained surgical specimens are created with the clinical SRS 18	  
microscope by mapping two Raman shifts: 2845cm-1, which corresponds to CH2 bonds that are 19	  
abundant in lipids (Fig. 2A), and 2930cm-1, which corresponds to CH3 bonds that predominate in 20	  
proteins and DNA (Fig. 2B). Assigning a subtracted CH3-CH2 image (Fig. 2C) to a blue channel 21	  
and assigning the CH2 image to the green channel results in an image with contrast that is 22	  
suitable for brain tumor detection (Fig. 2D)9. However, given the ultimate goal of creating an 23	  
7 	  
imaging system that produces histologic images that are familiar to clinicians10-12, we devised 1	  
SRH, a method of processing SRS images that is reminiscent of H&E staining (Fig. 2E). Unlike 2	  
previous methods for achieving virtual H&E images through hyperspectral SRS microscopy12, 3	  
SRH relies on only two Raman shifts (2845cm-1 and 2930cm-1) to generate the necessary 4	  
contrast. Though the colors in SRH images do not correspond exactly with the staining of acidic 5	  
(hematoxylin) or basic (eosin) moieties, there is strong overlap between the two methods (Fig. 6	  
2F), simplifying interpretation. To produce SRH images, fields-of-view (FOVs) are acquired at a 7	  
speed of 2 sec per frame in a mosaic pattern, stitched, and recolored. The end result is an SRH 8	  
mosaic (Fig. 2G) resembling a traditional H&E-stained slide. The time of acquisition for the 9	  
mosaic shown in Figure 2G is 2.5 min and it can be rapidly transmitted to any networked 10	  
workstation directly from an operating room.  11	  
 12	  
Detection of Diagnostic Histologic Features with SRH 13	  
We assessed the ability of SRH to reveal the diagnostic features required to detect and classify 14	  
tumors of the CNS by imaging fresh surgical specimens from 101 neurosurgical patients (Table 15	  
S1) via an IRB-approved protocol (UM IRB HUM00083059). Like conventional H&E images, 16	  
SRH images reveal the cellular and architectural features that permit differentiation of non-17	  
lesional (Fig. 3A-C) and lesional (Fig. 3D-I) and tissues. When imaged with SRH, architecturally 18	  
normal brain tissue from anterior temporal lobectomy patients (patients 6, 11, and 93) 19	  
demonstrates neurons with angular cell bodies containing lipofuscin granules (Fig. 3A), and 20	  
lipid-rich axons that appear as white linear structures (Fig. 3A-B). Non-neoplastic reactive 21	  
changes including gliosis (Fig. 3B) and macrophage infiltration (Fig. 3C) that may complicate 22	  
intraoperative diagnosis are also readily visualized with SRH. Key differences in cellularity, 23	  
8 	  
vascular pattern, and nuclear architecture that distinguish low-grade (Fig. 3D; patient 3) from 1	  
high-grade (Fig. 3E-F; patient 21) gliomas are apparent as well. Notably, SRH suggests that the 2	  
perinuclear halos of oligodendroglioma cells (Fig. 3D), not typically seen on frozen section and 3	  
thought to be an artifact of fixation13, are reflective of abundant protein-rich tumor cell 4	  
cytoplasm. In addition, by highlighting the protein-rich basement membrane of blood vessels, 5	  
SRH is well-suited for highlighting microvascular proliferation in high-grade glioma (Fig. 3F; 6	  
patient 37).  7	  
SRH also reveals the histoarchitectural features that enable diagnosis of tumors of non-8	  
glial origin (Fig. 3G-I), including the whorled architecture of meningiomas (Fig. 3G; patient 26), 9	  
the discohesive monomorphic cells of lymphoma (Fig. 3H; patient 31), and the glandular 10	  
architecture, large epithelioid cells, and sharp borders of metastatic adenocarcinoma (Fig. 3I; 11	  
patient 57). SRH is also capable of visualizing morphologic features that are essential in 12	  
differentiating the three most common pediatric posterior fossa tumors—juvenile pilocytic 13	  
astrocytoma, medulloblastoma, and ependymoma—each of which have divergent goals for 14	  
surgical management14. In pilocytic astrocytomas, SRH detects piloid (hair-like) architecture and 15	  
Rosenthal fibers, which appear dark on SRH due to their high protein content (Fig. S2A; patient 16	  
98). SRH also reveals the markedly hypercellular, small, round, blue cell appearance and rosettes 17	  
in medulloblastoma (Fig. S2B; patient 101), as well as the monomorphic round-to-oval cells 18	  
forming perivascular pseudorosettes in ependymoma (Fig. S2C; patient 87).  19	  
 20	  
Detection of Intratumoral Heterogeneity with SRH 21	  
Gliomas often harbor histologic heterogeneity, which complicates diagnosis and treatment 22	  
selection. Heterogeneity is particularly common in low-grade gliomas suspected of having 23	  
9 	  
undergone malignant progression, and demonstration of anaplastic transformation is essential for 1	  
making a diagnosis. SRH was successful in detecting heterogeneity of tumor grade within a 2	  
specimen collected from a patient with a recurrent oligodendroglioma of the right frontal cortex. 3	  
In that specimen, SRH revealed both low-grade architecture and areas of high-grade architecture 4	  
characterized by hypercellular, anaplastic, and mitotically active tumor (Fig. 4A, patient 41).  5	  
In other tumors, such as mixed glioneuronal tumors, histologic heterogeneity is a 6	  
necessary criterion for diagnosis: while any single histopathologic sample may reveal glial or 7	  
neuronal architecture, the identification of both is necessary for diagnosis. In a patient with 8	  
suspected ganglioglioma, a glioneuronal tumor, intraoperative SRH images of a superficial 9	  
specimen (Fig 4B; patient 96) revealed clustered dysplastic neurons, while a deep specimen 10	  
revealed hypercellular piloid glial architecture. Consequently, by providing a rapid means of 11	  
imaging multiple specimens, SRH reveals intratumoral heterogeneity needed to establish 12	  
clinically relevant variations in both grade and histoarchitecture during surgery.  13	  
 14	  
Quantitative Evaluation of SRH-Based Diagnosis 15	  
Given its ability to reveal diagnostic histologic features, we hypothesized that SRH could 16	  
provide an alternative to existing methods of intraoperative diagnosis. To test this hypothesis, we 17	  
imaged specimens from 30 neurosurgical patients where intraoperative diagnosis was rendered 18	  
using routine frozen sectioning or cytological techniques (Table S1, patients 72-101). Adjacent 19	  
portions of the same specimens were utilized for both routine histology and SRH. 20	  
To simulate the practice of intraoperative histologic diagnosis, a computer-based survey 21	  
was created, in which three board-certified neuropathologists (K.A.M., S.R., M.S.), each 22	  
practicing at different institutions, were presented with SRH or routine (smear and/or frozen) 23	  
10 	  
images, along with a brief clinical history regarding the patient’s age group (child/adult), lesion 1	  
location, and relevant past medical history. The neuropathologists responded with an 2	  
intraoperative diagnosis for each case the way they would in their own clinical practices. 3	  
Responses were graded based on: 1) whether tissue was classified as lesional or non-lesional, 2) 4	  
for lesional tissues, whether they had a glial or non-glial origin, and 3) whether the response 5	  
contained the same amount of diagnostic information (lesional status, grade, histologic subtype) 6	  
as the official clinical intraoperative diagnosis.   7	  
Assessing the pathologists’ diagnostic performance when utilizing SRH versus clinical 8	  
frozen sections revealed near-perfect concordance (Cohen’s kappa) between the two histological 9	  
methods for distinguishing lesional and non-lesional tissues (κ=0.84-1.00) (Fig. 5A) and for 10	  
distinguishing lesions of glial origin from non-glial origin (κ=0.93-1.00) (Fig. 5B).  There was 11	  
also near-perfect concordance between the two modalities in predicting the final diagnosis 12	  
(κ=0.89-0.92) (Fig. 5C). Inter-rater reliability among reviewers and concordance between SRH 13	  
and standard H&E-based techniques for predicting diagnosis was also nearly perfect (κ=0.89-14	  
0.92). Notably, with SRH, the pathologists were highly accurate in distinguishing lesional from 15	  
non-lesional tissues (98%), glial from non-glial tumors (100%), and predicting diagnosis 16	  
(92.2%). These findings suggest that pathologists’ ability to derive histopathologic diagnoses 17	  
from SRH images is both accurate and highly concordant with traditional histological methods. 18	  
 19	  
Machine Learning-Based Tissue Diagnosis 20	  
Intraoperative image data that is most useful for clinical decision-making is that which is rapidly 21	  
obtained and accurate. Interpretation of histopathologic images by pathologists is labor- and 22	  
time-intensive and prone to inter-observer variability. Consequently, a system rapidly delivering 23	  
11 	  
prompt, consistent, and accurate tissue diagnoses would be greatly helpful during brain tumor 1	  
surgery. While we have previously shown that tumor infiltration can be predicted by quantitative 2	  
SRS images through automated analysis of tissue attributes6, we hypothesized that more robust 3	  
computational processing would be required to predict tumor diagnostic class.   4	  
We employed a machine learning process called a multilayer perceptron (MLP) for 5	  
diagnostic prediction because it is 1) easy to iterate, 2) easy to verify, and 3) efficient with 6	  
current computational power. To create the MLP, we incorporated 12,879 400x400µm SRH 7	  
FOVs from our series of 101 patients. We used WND-CHRM, an open-source image 8	  
classification program that calculates 2,919 image attributes for machine learning15 to assign 9	  
quantified attributes to each FOV. Normalized quantified image attributes were fed into the MLP 10	  
for training, iterating until the difference between the predicted and observed diagnoses was 11	  
minimized (see Methods section).  12	  
To test the accuracy of the MLP, we used a leave-one-out approach, wherein the training 13	  
set contained all FOVs except those from the patient being tested. This method maximizes the 14	  
size of the training set and eliminates possible correlation between samples in the training and 15	  
test sets. The MLP makes predictions on an individual FOV level, yielding probabilities that a 16	  
given FOV belongs to one of the four diagnostic classes: non-lesional, low-grade glial, high-17	  
grade glial, or non-glial tumor (including metastases, meningioma, lymphoma, and 18	  
medulloblastoma) (Fig. 6A). The four diagnostic classes were selected because they provide 19	  
critical information for informing decision-making during brain tumor surgery.  20	  
Given the histoarchitectural heterogeneity of CNS tumors and the fact that some 21	  
specimens may contain a mixture of normal and lesional FOVs, we judged the diagnostic 22	  
accuracy of the MLP based on the most common or modal-predicted diagnostic class of FOVs 23	  
12 	  
within each specimen (Fig. 6B). For example, while the specimen from patient 87 exhibited 1	  
some features of all diagnostic classes in various SRH FOVs (Fig. 6A), the MLP assigned the 2	  
low-grade glial category as the highest probability diagnosis in a preponderance of the FOVs 3	  
(Fig. 6B), resulting in the correct classification of this specimen as a low-grade glial tumor. 4	  
To evaluate the MLP in a test set of cases read by multiple pathologists, we applied the 5	  
leave-one-out approach on each of the 30 cases included in the survey described above (Fig. 5). 6	  
Based on modal diagnosis, the MLP accurately differentiated lesional from non-lesional 7	  
specimens with 100% accuracy (Fig. 7A). Additionally, the diagnostic capacity of the MLP for 8	  
classifying individual FOVs as lesional or non-lesional was excellent, with 94.1% specificity and 9	  
94.5% sensitivity (AUC=0.984 [Fig. S3]). Among lesional specimens, the MLP differentiated 10	  
glial from non-glial specimens with 90% accuracy at the sample level (Fig. 7B). The modal 11	  
diagnostic class predicted by the MLP was 90% accurate in predicting the diagnostic class 12	  
rendered by pathologists in the setting of our survey (Fig. 7C). 13	  
The cases misclassified by the MLP included a minimally hypercellular specimen with 14	  
few Rosenthal fibers from a pilocytic astrocytoma (patient 84) classified as non-lesional, rather 15	  
than low-grade glioma. In this specimen, many of the FOVs resemble normal glial tissue (Fig. 16	  
S4A). Another misclassified specimen from a patient with leptomeningeal metastatic carcinoma 17	  
(patient 72) contained only 2 FOVs containing tumor (Fig. S4B). The glioblastoma specimen 18	  
from patient 82 (Fig. S4C), misclassified as a non-glial tumor by the MLP, contained protein-19	  
rich structural elements that resembled the histoarchitecture of metastatic tumors imaged with 20	  
SRH (Fig. S4D, patient 85). Despite these errors, the accuracy and overall ability of the MLP in 21	  
automated detection of lesional status and diagnostic category provides proof-of-principle for 22	  
how the MLP could be used for automated diagnostic predictions. 23	  
13 	  
DISCUSSION 1	  
Accurate intraoperative tissue diagnosis is essential during brain tumor surgery. Surgeons and 2	  
pathologists rely on trusted techniques such as frozen sectioning and smear preparations that are 3	  
reliable but prone to artifacts that limit interpretation and may delay surgery. A simplified 4	  
standardized method for intraoperative histology would create the opportunity to use 5	  
intraoperative histology to ensure more efficient, comprehensive sampling of tissue within and 6	  
surrounding a tumor. In this manuscript, we report the first demonstration of SRS microscopy in 7	  
a clinical setting and show how it can be used to rapidly create histologic images from fresh 8	  
specimens with diagnostic value comparable to conventional techniques.    9	  
Fluorescence-guided surgery16, mass spectrometry17, Raman spectroscopy18, coherent 10	  
anti-Stokes Raman scattering microscopy19,20, and optical coherence21 tomography, which 11	  
exploit histologic and biochemical differences between tumor-infiltrated and normal tissues, 12	  
have been proposed as methods for guiding excision of brain and other types of tumors22,23. To 13	  
date, however, no microscopic imaging modality tested in a clinical setting has been successful 14	  
in rapidly creating diagnostic-quality images to inform intraoperative decision-making. Here we 15	  
show that by leveraging advances in optics and fiber-laser engineering, it is possible to create an 16	  
SRS microscope that is easy to operate, durable, and compatible with a patient care environment, 17	  
which rapidly provides diagnostic histopathologic images. 18	  
SRH is well-suited for integration into the existing workflow for brain tumor surgery. A 19	  
surgical instrument that can simultaneously collect biopsies for SRH and be tracked by a 20	  
stereotactic navigational system would enable the linkage of histologic and positional 21	  
information in a single display, as suggested by Sanai et al.24. Integration of SRH and surgical 22	  
navigation would create the possibility of verifying that maximal safe cytoreduction has been 23	  
14 	  
executed throughout a surgical cavity. In situations where tumor is detected by SRH but cannot 1	  
be safely removed, it might be possible to serve as a way to better focus the delivery of adjuvant 2	  
therapies.  3	  
As medical data become increasingly computer-based, the opportunity to acquire virtual 4	  
histologic sections via SRS microscopy creates numerous opportunities. For example, in many 5	  
clinical settings where brain tumor surgery is carried out, neuropathology services are not 6	  
available. Currently there are 785 board-certified neuropathologists serving the approximately 7	  
1,400 hospitals performing brain tumor surgery in the United States (Table S2). A networked 8	  
SRS microscope, like the prototype introduced here, streamlines both sample preparation and 9	  
imaging and creates the possibility of connecting expert neuropathologists to surgeons—either 10	  
within the same hospital or in another part of the world—to deliver precise intraoperative 11	  
diagnosis during surgery.   12	  
Computer-aided diagnosis may ultimately reduce the inter-reader variability inherent in 13	  
pathologic diagnosis and might provide guidance in settings where an expert neuropathologist is 14	  
not available. Our results and the work of others suggest that machine learning algorithms can be 15	  
used to detect and diagnose brain tumors. Prior work in computer-aided diagnosis in 16	  
neuropathology has shown promise in differentiating diagnostic entities in formalin-fixed, 17	  
paraffin-embedded, H&E-stained whole slide images25,26.  The ideal computer-aided diagnostic 18	  
system for intraoperative histology would reliably predict diagnosis in small fresh tissue 19	  
samples. The classifier reported here is capable of distinguishing lesional from non-lesional 20	  
tissue samples and in predicting diagnostic class based on pooled tile data. In the future, we 21	  
anticipate that a machine learning approach will be capable of finer diagnostic classification. We 22	  
also hypothesize that the accuracy of diagnostic classifiers might also be improved via 1) 23	  
15 	  
exploring alternative neural network configurations and systems for convolution; 2) employing 1	  
feature-based classification; 3) utilizing support vector machines or statistical modeling 2	  
approaches; and 4) applying rules for data interpretation that account for demographic factors 3	  
and medical history.  4	  
 5	  
OUTLOOK 6	  
 SRS microscopy can now be utilized to provide rapid intraoperative assessment of tissue 7	  
architecture in a clinical setting with minimal disruption to the surgical workflow. SRH images 8	  
may ultimately be used to render diagnosis in brain tumor specimens with a high degree of 9	  
accuracy and near-perfect concordance with standard intraoperative histologic techniques. 10	  
Prospective, randomized clinical studies will be necessary to validate these results and define 11	  
how SRH can be used to expedite clinical decision-making and improve the care of brain tumor 12	  
patients.  13	  
 14	  
 15	  
MATERIALS AND METHODS 16	  
Study Design 17	  
The inclusion criteria for this study were as follows: 1) males and females; 2) subjects 18	  
undergoing brain tumor resection at the University of Michigan Health System (UMHS); 3) 19	  
subjects (or designee) able to provide informed consent; and 4) subjects in which there was 20	  
excess tumor tissue beyond what was needed for routine diagnosis. The sample size was 21	  
estimated at 100 patients to ensure adequate representation of all major tumor types for analysis 22	  
and based on the design of prior studies comparing SRS and H&E. The central goals of this 23	  
16 	  
study were: 1) to build and verify the first clinical SRS microscope; 2) to judge SRH as a means 1	  
of providing diagnostic histopathologic images; 3) to determine if machine learning could 2	  
accurately classify SRH images fresh human brain tumor specimens. We began by collecting 3	  
biopsies (N=125) from neurosurgical patients undergoing tumor resection (n=98) or anterior 4	  
temporal lobectomy (n=3). Each specimen was imaged immediately after removal with SRS 5	  
microscopy. A trained neuropathologist (S.C.P) then classified each biopsy based on WHO 6	  
diagnostic criteria13. We then quantified the correlation between SRH and H&E tissue imaging 7	  
through a survey administered to neuropathologists (S.R., M.S., K.M.). To quantify the SRH 8	  
images, we utilized WND-CHRM, which assigns 2,919 attributes to each image. We then used 9	  
the quantified image attributes to build and train an MLP to classify the images based on 10	  
diagnostic class. Diagnostic predictions were rendered based on the diagnostic class predicted 11	  
most commonly by the MLP for FOVs in a given specimen. 12	  
 13	  
Tissue Collection and Imaging 14	  
All tissues were collected in the context of a University of Michigan Medical School IRB-15	  
approved protocol from patients who provided informed consent (HUM0000083059). Tissues in 16	  
excess of what was needed for diagnosis were eligible for imaging. In a subset of patients where 17	  
the frozen section was large enough to split (patients 72-101), half of the specimen was routed 18	  
for SRH imaging, while half of the specimen became the tissue for clinical frozen section 19	  
diagnosis. 20	  
To image tissue with the clinical SRS microscope, a small (approximately 3mm) portion 21	  
of fresh tissue was placed on a standard uncoated glass slide in the center of a small piece of 22	  
two-sided tape (120µm thickness) in a manner similar to a standard squash preparation. Normal 23	  
17 	  
saline (50µL) was applied to the tissue and a coverslip was applied to the tissue and adhered to 1	  
the slide, creating a chamber for imaging. This slide was then placed on a motorized stage and 2	  
focused using standard transmission light microscopy. Using custom scripts in µ-Manager 3	  
software and ImageJ software, two-channel (2845cm-1 and 2930cm-1) images were obtained in a 4	  
mosaic fashion.  5	  
Our prototype system is built on an Olympus microscope body, and we developed a fully 6	  
custom beam-scanning unit that seamlessly integrates the laser source through fiber delivery. We 7	  
also developed control electronics for both the laser and the microscope. Our custom imaging 8	  
software is based on the open-source microscopy platform µ-Manager. The imaging system 9	  
appears as a “camera,” allowing us to leverage all the automated microscopy features provided 10	  
by the µ-Manager environment to enable multi-color mosaic imaging.	  11	  
 12	  
Virtual H&E Coloring 13	  
Generating a virtual H&E image from the 2845cm-1 and 2930cm-1 images acquired from the SRS 14	  
microscope utilizes a simple linear color-mapping of each channel. After channel subtraction and 15	  
flattening (described in the following section), a linear color remapping is applied to both the 16	  
2845cm-1 and the 2930cm-1 channel. The 2845cm-1 image, a grayscale image, is linearly mapped 17	  
such that a strong signal in the 2930cm-1 image maps to an eosin-like reddish-pink color instead 18	  
of white. A similar linear mapping is applied to the 2930cm-1 image with a hematoxylin-like 19	  
dark-blue/violet color mapped to a strong signal. Finally, these two layers are linearly added 20	  
together to result in the final virtual-colored H&E image.  21	  
The exact colors for the H&E conversion were selected by a linear optimization based on 22	  
a collection of true H&E-stained slides created by the UMHS Department of Pathology. An 23	  
18 	  
initial seed color was chosen at random for both H&E conversions. The previously described 1	  
linear color-mapping and addition process was completed with these initial seed colors. The 2	  
ensuing image was hand-segregated into a cytoplasmic and nuclear portion. These portions were 3	  
compared with the true H&E images and a cytoplasmic and nuclear hue difference between 4	  
generated false-colored H&E and true H&E was elucidated. The H&E seed colors were modified 5	  
by these respective hue differences and the process was repeated until the difference between 6	  
generated and true images was less than 1% different by hue. 7	  
 8	  
Image Acquisition and Stitching 9	  
The procedure for generating a virtual-colored H&E image from the SRS microscope consists of 10	  
6 discrete steps: 11	  
1) A mosaic acquisition script is started on the control computer that acquires an (NxN) 12	  
series of 1024x1024 pixel images from a pre-loaded tissue sample. These images are 13	  
acquired at the 2845cm-1 and 2930cm-1 Raman shifts and saved as individual two-channel 14	  
FOVs to a pre-specified folder.  15	  
2) The two-channel image is duplicated and a Gaussian blur is applied to the duplicated 16	  
image. The original two-channel image is then divided by the Gaussian blur to remove 17	  
artifacts of acquisition and tissue preparation. 18	  
3) The 2845cm-1 channel is subtracted from the 2930cm-1 channel in each FOV.  19	  
4) New FOVs are created with the 2845cm-1 channel and the 2930cm-1 minus 2845cm-1 20	  
channel.  21	  
5) The virtual-color H&E script (described in the above section) is run to create an H&E 22	  
version of the subtracted and flattened tile. 23	  
19 	  
6)  The original tile is stitched as previously described27. The user is presented with an 1	  
option to re-stitch with different stitching parameters if the initial stitch produces an 2	  
unacceptable image. Upon successful stitching, a layout file is generated from the 3	  
terminal positions of the individual tiles in the stitched image. 4	  
7) The virtual-color H&E images are stitched using the layout file generated in step #6, a 5	  
significantly faster process than re-computing the stitching offsets and merges from 6	  
scratch. 7	  
 8	  
Survey Methodology 9	  
A computer-based survey consisting of 30 patients was developed and given to blinded 10	  
neuropathologists (K.A.M, S.R., M.S.), who were presented with standard frozen H&E images 11	  
and SRH images. All cases included in the survey were judged to have SRH and conventional 12	  
H&E preparations that contained the essential architectural features required for diagnosis. Each 13	  
image was accompanied by a short clinical history that included age group, sex, and presenting 14	  
symptom(s). Survey responses were recorded automatically by the survey software. The 15	  
intraoperative frozen and final pathologic diagnoses determined by standard clinical protocol 16	  
employed by the UMHS Department of Pathology were also recorded. The survey responses 17	  
were scored for accuracy on four levels: 1) for all specimens, whether tissue was lesional vs. 18	  
non-lesional; 2) for lesional tissues, whether the origin was glial or non-glial; 3) for glial tumors, 19	  
whether the tumor was low- or high-grade; and 4) for all tumors, the predicted diagnosis. 20	  
Responses were considered concordant if accuracy scores were equal. The maximum possible 21	  
score for each case was determined by the clinical frozen section diagnosis. For each case, the 22	  
20 	  
following diagnoses were used for statistical analysis: UMHS frozen section diagnosis, survey 1	  
frozen section diagnosis, survey SRH diagnosis.  2	  
 3	  
Statistical Analysis 4	  
For each pathologist, we calculated Cohen’s kappa28 for SRH vs. H&E for lesion/no lesion and 5	  
for glioma/no glioma.  This provides information on how well SRH and H&E agree. 6	  
Kappa was also calculated for final diagnosis from SRH vs. truth (clinical frozen section 7	  
diagnosis) and for H&E vs. truth (clinical frozen section diagnosis), where final diagnosis was 8	  
one of eleven categories, which tells us how well each pathologist was able to detect the truth 9	  
from either SRH or H&E. Lastly, we calculated the three-reader inter-rater reliability (Fleiss’ 10	  
kappa29) for SRH lesion/no lesion, SRH glioma/no glioma, H&E lesion/no lesion, and for H&E 11	  
glioma/no glioma. R software was used for all statistical analyses. 12	  
No distributional assumptions are necessary for the kappa statistic.  The only assumption is that 13	  
the data are categorical and that SRH and H&E are measured on the same data, which they are. 14	  
There is no estimate of variance for groups. 15	  
 16	  
Generation of the MLP 17	  
The MLP was programmed with two software libraries: Theano and Keras. Theano 18	  
(http://deeplearning.net/software/theano/index.html) is a high-performance low-level 19	  
mathematical expression evaluator used to train the MLP. Keras (http://keras.io) is a high-level 20	  
Python framework that serves as a wrapper for Theano, allowing rapid iteration and testing of 21	  
different MLP configurations.   22	  
21 	  
The MLP is designed as a fully-connected, 1,024-unit, 1 hidden layer, neural network. It 1	  
comprises 8 sequential layers in the following order: 1) dense input layer with uniform 2	  
initialization; 2) hyperbolic tangent activation layer; 3) dropout layer with dropout probability 3	  
0.2; 4) dense hidden layer with uniform initialization; 5) hyperbolic tangent activation layer; 6) 4	  
dropout layer with dropout probability 0.2; 7) dense output layer with uniform initialization; and 5	  
8) a softmax activation layer corresponding to the number of classifications (Fig. S5).  6	  
Training of the MLP was performed using a training set that was exclusive from the 7	  
survey test set. Loss was calculated using the multiclass log-loss strategy. The selected optimizer 8	  
was the “Adam” optimizer. The optimizer’s parameters were as follows: learning rate= 0.001, 9	  
beta_1=0.9, beta_2=0.999, and epsilon=1x10-8. 10	  
 11	  
Image Processing and Analysis by the MLP 12	  
The process to convert a raw SRH image to a probability vector for each of the diagnoses is as 13	  
follows: 14	  
1) Use FIJI to subtract the CH2 layer from the CH3 layer and flatten the image as described 15	  
in the subsection “Tissue Collection and Imaging.” 16	  
2) Use FIJI to split the two-channel image into a separate CH2 layer and a CH3-CH2 layer.  17	  
3) For each of the previous tiles, create 4 duplications of the tile with 90-degree rotations 18	  
(“rotamers”).  19	  
4) Use WNDCHRM (http://scfbm.biomedcentral.com/articles/10.1186/1751-0473-3-13) to 20	  
generate signature files for each of the tiles from the previous step. 21	  
5) Normalize the signature files such that all of the feature values are uniformly and linearly 22	  
mapped to the range (-1.0, 1.0). 23	  
22 	  
6) (CH2). For each of the tiles that correspond to CH2-channel tiles, run the MLP as 1	  
described above. 2	  
7) (CH2). Gather all of the rotamers for a given tile and average (arithmetic mean) the 3	  
prediction values from them to create one consolidated diagnosis-probability vector for a 4	  
given CH2-channel tile. 5	  
8) Repeat steps 6-7 for the CH3-CH2 channel. 6	  
9) For a given tile, compare the CH2-channel and the CH3-CH2 channel and discard the 7	  
diagnosis-probability vector for the tile that has a lower maximal probability value. 8	  
10) For a case-by-case diagnosis, group all of the tiles for a case, remove any tile that doesn’t 9	  
have a diagnosis probability of >0.25, and diagnose the case with the most prevalent 10	  
(mode) diagnosis among the set of tiles. 11	  
 12	  
MLP Evaluation with the Leave-One-Out Approach 13	  
To test the diagnostic accuracy of the MLP, we used a leave-one-out approach for the 30 patients 14	  
that were used in the survey administered to neuropathologists. For each of the 30 patients used 15	  
to evaluate the MLP, all FOVs (n) from that patient were placed in the test set. The training set 16	  
was composed of the 12,879-n remaining FOVs. The 12,879 FOVs were screened by a 17	  
neuropathologist to ensure they were representative of the diagnosis they were assigned to. FOVs 18	  
were classified as non-lesional, pilocytic astrocytoma, ependymoma, oligodendroglioma, low-19	  
grade diffuse astrocytoma, anaplastic oligodendroglioma, anaplastic astrocytoma, glioblastoma, 20	  
meningioma, lymphoma, metastatic tumor, and medulloblastoma.  21	  
The MLP was trained for 25 iterations, with the following 26 iteration weights recorded 22	  
to use for validation of the test set. The test set was fed into each of these 26 weights with the 23	  
23 	  
resulting probabilities of each of the 12 diagnostic classes averaged to create a final probability 1	  
for each diagnosis for each FOV. The 12 diagnoses were condensed to four classes (non-lesional, 2	  
low-grade glial, high-grade glial, and non-glial) to achieve diagnostic predictions. The low-grade 3	  
glial category included FOVs classified as pilocytic astrocytoma, ependymoma, 4	  
oligodendroglioma, and low-grade diffuse astrocytoma. The high-grade glial category included 5	  
FOVs classified as anaplastic oligodendroglioma, anaplastic astrocytoma, and glioblastoma. The 6	  
non-glial category included FOVs classified as meningioma, lymphoma, metastatic tumor, and 7	  
medulloblastoma. 8	  
 9	  
Nationwide Inpatient Sample Query 10	  
The Nationwide Inpatient Sample (NIS) database, obtained from the Healthcare Cost and 11	  
Utilization Project of the Agency for Healthcare Research and Quality, was queried for years 12	  
2010 and 2011.  The NIS for these years contains discharge data for all discharges from a sample 13	  
of hospitals representing 20% of all nationwide discharges from nonfederal hospitals using a 14	  
stratified random sampling technique.   15	  
Brain tumor resections or biopsies were identified using combinations of International 16	  
Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) diagnosis and 17	  
treatment codes that were previously used for studies of adult tumors30, pediatric tumors31, and 18	  
pituitary tumors32. Primary tumor ICD-9 diagnosis and procedure code codes used include 191.0-19	  
191.9, 225.0, 237.5, and 01.53, 01.59, 01.13, 01.14, respectively. Meningioma ICD-9 diagnosis 20	  
and procedure codes used include 225.2, 192.1, 237.6, and 01.51, 01.13, and 01.14, respectively. 21	  
Diagnosis code 198.3 and procedure codes 01.53, 01.59, 01.13, and 01.14 were used for 22	  
metastases. Diagnosis code 225.1 and procedure code 04.01 was used for vestibular 23	  
24 	  
schwannomas. Diagnosis code 227.3 and procedure codes 07.62 and 07.65 were used for 1	  
pituitary tumors. 2	  
  3	  
Code Availability 4	  
To access code utilized in generation of data in this study, please contact corresponding author 5	  
(DO). 6	  
 7	  
“NOT FOR CLINICAL USE” STATEMENT 8	  
The SRS microscopy system described in this publication is a prototype system that is intended 9	  
for research use only. It does not comply with international safety standards nor has it received 10	  
approval or clearance from any government agency such as the U.S. Food and Drug 11	  
Administration (FDA). Validation has been demonstrated on ex vivo tissue specimens as 12	  
approved by University of Michigan IRB protocol (HUM00083059). 13	   	  14	  
25 	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Fig. 1. Engineering a clinical SRS microscope. (A) SRS microscope in the UMHS operating 1	  
room. (B) Key components of the dual-wavelength fiber-laser-coupled microscope required to 2	  
create a portable, clinically compatible SRS imaging system. The top arm of the laser diagram 3	  
indicates the scheme for generating the Stokes beam (red), while the bottom arm generates the 4	  
pump beam (orange). Both beams are combined (purple) and passed through the specimen. (C) 5	  
Raw 2845cm-1 image of human tissue before, and (D) after balanced-detection-based noise 6	  
cancellation. HNLF = highly non-linear fiber; PPLN = periodically poled lithium niobate; PD = 7	  
photo diode. 8	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 1	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Fig. 2. Creating virtual H&E slides with the clinical SRS microscope. (A) CH2 and (B) CH3 3	  
images are acquired and (C) subtracted. (D) The CH2 image is assigned to the green channel, 4	  
and CH3-CH2 image is assigned to the blue channel to create a two-color blue-green image. 5	  
Applying an H&E lookup table, SRH images (E) are comparable to a similar section of tumor 6	  
(F) imaged after formalin-fixation, paraffin-embedding (FFPE), and H&E staining. (G) Mosaic 7	  
tiled image of several SRH FOVs to create a mosaic of imaged tissue. Asterisk (*) indicates a 8	  
focus of microvascular proliferation, dashed circle indicates calcification, and the dashed box 9	  
demonstrates how the FOV in (E) fits into the larger mosaic. Scale bars = 100µm. 10	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Fig. 3. Imaging of key diagnostic histoarchitectural features with SRH. (A) Normal cortex 3	  
reveals scattered pyramidal neurons (blue arrowheads) with angulated boundaries and lipofuscin 4	  
granules, which appear red. White linear structures are axons (green arrowheads). (B) Gliotic 5	  
tissue contains reactive astrocytes with radially directed fine protein-rich processes (red 6	  
arrowheads) and axons (green arrowheads). (C) A macrophage infiltrate near the edge of a 7	  
glioblastoma reveals round, swollen cells with lipid-rich phagosomes. (D) SRH reveals scattered 8	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“fried-egg” tumor cells with round nuclei, ample cytoplasm, perinuclear halos (yellow 1	  
arrowheads), and neuronal satellitosis (purple arrowhead) in a diffuse 1p19q-co-deleted low-2	  
grade oligodendroglioma. Axons (green arrowhead) are apparent in this tumor-infiltrated cortex 3	  
as well. (E) SRH demonstrates hypercellularity, anaplasia, and cellular and nuclear 4	  
pleomorphism in a glioblastoma. A large binucleated tumor cell is shown (inset) in contrast to 5	  
smaller adjacent tumor cells. (F) SRH of another glioblastoma reveals microvascular 6	  
proliferation (orange arrowheads) with protein-rich basement membranes of angiogenic 7	  
vasculature appearing purple. SRH reveals (G) the whorled architecture of meningioma (black 8	  
arrowheads), (H) monomorphic cells of lymphoma with high nuclear:cytoplasmic ratio, and (I) 9	  
the glandular architecture (inset; gray arrowhead) of a metastatic colorectal adenocarcinoma.  10	  
Large image scale bars = 100µm; inset image scale bars =20µm. 11	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 13	  
 14	  
 15	  
 16	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 18	  
 19	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Fig. 4. SRH reveals structural heterogeneity in human brain tumors. (A) A patient with a 1	  
history of low-grade oligodendroglioma was followed for an enlarging enhancing mass (yellow 2	  
arrowhead) in the previous resection cavity (red circle). SRH imaging of the resected tissue 3	  
reveals areas with low-grade oligodendroglioma architecture in some regions (top) with foci of 4	  
anaplasia (bottom) in other areas of the same specimen. FFPE H&E images are shown for 5	  
comparison. (B) Gangliogliomas are typically composed of neuronal and glial components. SRH 6	  
reveals architectural differences between a shallow tissue biopsy (green arrowhead) where 7	  
disorganized binucleated dysplastic neurons predominate (top), and a deeper biopsy (blue 8	  
arrowhead) where architecture is more consistent with a hypercellular glioma (bottom).  FFPE 9	  
H&E images are shown for comparison. 10	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Fig. 5. Simulation of intraoperative histologic diagnosis with SRH. A web-based survey 1	  
consisting of specimens from 30 patients (patients 72-101) imaged with both SRH and 2	  
conventional H&E methods was administered to three neuropathologists. Neuropathologists 3	  
recorded free-form responses as they would during a clinical intraoperative histologic consult. 4	  
Responses were graded based on whether tissue was judged as (A) lesional or non-lesional, (B) 5	  
glial or non-glial, and (C) on the accuracy of diagnosis. SRH and H&E preparations for six 6	  
examples of portions of specimens presented in the survey are shown: gliotic brain tissue (patient 7	  
91), medulloblastoma (patient 101), anaplastic astrocytoma (patient 76), meningioma (patient 8	  
95), glioblastoma (patient 82), and metastatic carcinoma (patient 74). Scale bars = 50µm.   9	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Fig. 6. MLP classification of SRH images. The specimen from patient 87, a low-grade 3	  
ependymoma, was classified by the MLP as a low-grade glial tumor. (A) An SRH mosaic 4	  
depicting the low-grade glial tumor diagnostic class with individual FOVs designated by dashed 5	  
lines (center). Four individual FOVs are depicted at higher scale, with the MLP diagnostic 6	  
probability for all four categories listed above (P(NL) = probability of non-lesional; P(LGG) = 7	  
probability of low-grade glial; P(HGG) = probability of high-grade glial; P(NG) = probability of 8	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non-glial). Representative FOVs include a FOV with a small number of ovoid tumor cells 1	  
(arrowhead) classified as low-grade glioma (top left, orange outline), a FOV with high cellularity 2	  
with frequent hyalinized blood vessels (arrowheads) classified as non-glial tumor (top right, 3	  
green outline), a FOV with moderate cellularity and abundant piloid processes (bottom right, 4	  
yellow outline) classified as a low-grade glioma, and a FOV with higher cellularity and several 5	  
prominent vessels (arrowheads) classified as high-grade glial tumor (bottom left, blue outline). 6	  
Scale bars are 100µm for the individual FOVs and 500µm for the mosiac image. (B) Probability 7	  
heatmaps overlaid on the SRH mosaic image indicate the MLP-determined probability of class 8	  
membership for each FOV across the mosaic image for the four diagnostic categories. Colored 9	  
boxes correspond to the FOVs highlighted in A.  10	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Fig 7. MLP-based diagnostic prediction. (A) Heat map depiction of the classification of cases 2	  
as lesional or non-lesional via MLP. Green checks indicate correct MLP prediction, red circles 3	  
indicate incorrect prediction. (B) Heat map depiction of the classification of cases as glial or non-4	  
glial via MLP. Green checks indicate correct MLP prediction, red circles indicate incorrect 5	  
prediction. (C) Summary of MLP results from test set of 30 neurosurgical cases (patients 72-6	  
101). The fraction of correct tiles is indicated by the hue and intensity of each heat map tile, as 7	  
well as the predicted diagnostic class.  8	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SUPPLEMENTAL MATERIALS 1	  
 2	  
 3	  
 4	  
Fig. S1. Axial and lateral resolution of the clinical SRS microscope. (A) XZ image of a 5	  
300nm polystyrene bead generated from a 1000 x 1000 x 40 pixel image stack with 100nm 6	  
sampling in each dimension. (B) Lateral full width of half maximum (FWHM) is 360nm. (C) 7	  
Axial FWHM is 1.8µm. 8	  
 9	  
 10	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Fig. S2. SRH of pediatric posterior fossa tumors. (A) SRH reveals Rosenthal fibers (dashed 2	  
box) in a pilocytic astrocytoma, which appear dark, given their protein-rich nature. The hair-like, 3	  
piloid architecture of these moderately hypercellular tumors is apparent as well. (B) 4	  
Medulloblastoma with marked hypercellularity, nuclear molding and pleomorphism, rosettes 5	  
(dashed circle) and microvascular proliferation contrasts sharply with pilocytic astrocytoma. (C) 6	  
Monomorphic, round-to-oval cells that encircle blood vessels in pseudorosettes are demonstrated 7	  
in ependymoma.  Scale bars = 100 µm. 8	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Figure S3: MLP performance at FOV level for lesional classification. The MLP assigns 4	  
probabilities of membership to each FOV in one of four classes: non-lesional, low-grade glial, 5	  
high-grade glial or non-glial tumor. The categories can be condensed into non-lesional and 6	  
lesional (low-grade glial, high-grade glial and non-glial tumor) classes yielding a probability that 7	  
a FOV is lesional or non-lesional.  (A) Ability of MLP prediction probability to distinguish 8	  
lesional from non-lesional FOVs shown by ROC analysis of all 1823 FOVs from the 30 survey 9	  
cases. (B) The contingency table and sensitivity and specificity metrics at the MLP probability 10	  
threshold optimizing sensitivity and specificity.  11	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Figure S4: Cases incorrectly classified by the MLP. (A) A specimen from a pilocytic 2	  
astrocytoma (patient 84) demonstrating predominantly normal appearing glial tissue that is 3	  
minimally hypercellular with rare Rosenthal fibers (green arrowhead). (B) In a specimen from a 4	  
metastatic carcinoma (patient 72), the area imaged contained two small nests of carcinoma 5	  
(yellow arrowheads) that were essential in making the diagnosis. (C) The glioblastoma shown 6	  
here (patient 82) contained angiogenic blood vessels with prominent protein deposition in their 7	  
walls (black arrowheads) and resemble the fibrous stromal elements (black arrowheads) 8	  
characteristically observed in metastatic carcinomas (patient 85).  9	  
 10	  
 11	  
 12	  
 13	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Fig. S5. Process/program design for creation of the multilayer perceptron. 43	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Table S1: Descriptive Statistics of the Case Series 1	  
Patient 
Age 
(yrs) Sex 
Tumor 
Location 
Frozen Section 
Diagnosis Final Diagnosis 
1 52 M Right temporal Cortex with gliosis, 
rare atypical cells 
Anaplastic astrocytoma, WHO 
grade III 
2 44 M Left insular Glioma, favor low-
grade 
Low grade glioma 
3 36 F Right frontal  Low-grade glioma  Oligodendroglioma 
4 55 F Right frontal  Glioma Glioblastoma 
5 33 F Left parietal Meningioma 
Meningioma 
6 33 F Left temporal n/a Normal neocortex/hippocampal 
sclerosis 
7 62 F Right Parietal Glioblastoma Glioblastoma 
8 53 F Left parietal  Glioblastoma Glioblastoma 
9 29 M Left frontal Infiltrating glioma Astrocytoma, WHO grade II 
10 57 M Right 
temporoparietal 
n/a Metastatic bladder 
adenocarcinoma 
11 34 M Left temporal  n/a Normal neocortex/hippocampal 
sclerosis 
12 27 
M 
Right temporal Gliotic brain tissue 
with atypical cells 
Diffuse astrocytoma, WHO grade 
II 
13 49 M Left parietal  Recurrent glioma Recurrent glioblastoma, with 
treatment effect  
14 51 M Right frontal  High-grade glioma Glioblastoma 
15 70 M Left temporal Necrosis, gliosis, 
atypical cells  
Glioblastoma 
16 68 F Right frontal    High-grade neoplasm Gliosarcoma 
17 63 F 
Left frontal 
Malignant neoplasm, 
favor metastasis 
Metastatic melanoma 
18 62 M Right parietal Metastatic carcinoma Metastatic ovarian 
adenocarcinoma 
19 61 F Right parietal  
Scattered glioma cells 
Glioblastoma 
48 	  
20 77 M Right parietal Glioblastoma Glioblastoma 
21 50 F Left temporal Infiltrating glioma Anaplastic astrocytoma, WHO 
grade III 
22 
34 F Posterior fossa Infiltrating glioma Recurrent infiltrating glioma 
23 55 M Right frontal Infiltrating glioma Glioblastoma 
24 
12 
F Posterior fossa Glial tumor Pilocytic astrocytoma 
25 57 M Left 
temporoparietal 
Recurrent glioma 
Glioblastoma 
26 51 F Right 
frontotemporal  
Meningioma Meningioma 
27 69 F 
Left temporal  
High-grade glioma Anaplastic oligodendroglioma, 
WHO grade III 
28 51 M Right temporal Infiltrating glioma Diffuse astrocytoma, WHO grade 
II 
29 
67 F Parasagittal Meningioma Meningioma 
30 70 F Left parietal  n/a  Recurrent atypical meningioma 
31 70 M 
Right insular  
Glioblastoma Glioblastoma 
32 64 F 
Right temporal 
Glioma Diffuse astrocytoma, WHO grade 
II 
33 49 M Left parietal 
Meningioma 
Meningioma 
34 38 F Left occipital Meningioma Meningioma 
35 30 M Left occipital  n/a Cortical dysplasia 
36 13 M Posterior fossa  Medulloblastoma Medulloblastoma  
37 40 M Spinal cord Glial neoplasm, favor 
astrocytoma 
Glioblastoma 
38 62 F Right temporal Lesional tissue  Diffuse astrocytoma, WHO grade 
II 
39 74 M Right frontal High-grade glioma Glioblastoma 
40 51 M Right parietal  Malignant neoplasm, 
favor metastasis 
Metastatic melanoma 
49 	  
41 54 M Right parietal  Recurrent glioma Recurrent glioma, WHO grade II 
42 24 F Left occipital Metastasis  Metastatic breast adenocarcinoma 
43 29 M Left frontal  Lesional tissue  Recurrent anaplastic 
astroblastoma  
44 66 M 
Posterior fossa 
Ependymoma Recurrent ependymoma, WHO 
grade II 
45 45 M Right 
frontotemporal 
Recurrent glioma Glioblastoma 
46 65 M Right occipital  Metastatic carcinoma Metastatic lung adenocarcinoma 
47 56 M Left parietal 
Glioblastoma 
Glioblastoma 
48 46 M Left frontal Glioma Anaplastic astrocytoma, WHO 
grade III 
49 7 M Posterior fossa Glioma, favor pilocytic 
astrocytoma 
Pilocytic astrocytoma 
50 54 F Left frontal Glioblastoma Glioblastoma 
51 69 F Left frontal Glioblastoma 
Recurrent glioblastoma 
52 57 F Left frontal  Meningioma Meningioma 
53 
49 F Left frontal  Glioma Anaplastic oligodendroglioma, 
WHO grade III 
54 
33 
F Right frontal  Glioma Anaplastic astrocytoma, WHO 
grade III 
55 69 
F 
Right parietal  Meningioma Meningioma  
56 58 F Left frontal Glioblastoma Glioblastoma 
57 48 M Left frontal  
Metastatic 
adenocarcinoma Metastatic adenocarcinoma 
58 68 F Right frontal  Metastatic carcinoma Metastatic carcinoma 
59 20 F Right frontal  Low-grade 
glioneuronal neoplasm 
Ganglioglioma, WHO Grade I 
60 52 F Right temporal  Glioma  Anaplastic oligodendroglioma, 
WHO grade III 
61 78 F Right frontal  Glioblastoma Glioblastoma 
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62 
40 F Right frontal  Metastatic carcinoma Metastatic carcinoma, ovarian  
63 40 F Left frontal  Glioblastoma Recurrent glioblastoma  
64 53 F Left frontal  Glioblastoma Glioblastoma 
65 34 
M 
Left temporal  Infiltrating glioma Oligodendroglioma, WHO grade 
II 
66 33 F Left parietal Meningioma Meningioma 
67 66 M Left occipital n/a 
Glioblastoma 
68 60 F Right frontal  Recurrent/residual 
glioma 
Anaplastic astrocytoma, WHO 
grade III 
69 4 M Posterior fossa Small round blue cell 
tumor 
Medulloblastoma 
70 53 M Right frontal Recurrent/residual 
high-grade glioma 
Glioblastoma 
71 61 F 
Right frontal 
Metastatic 
adenocarcinoma 
Metastatic adenocarcinoma, colon 
primary 
72 52 F Cerebellar Metastatic carcinoma Metastatic lung 
adenocarcinoma 
73 36 M Right frontal Low-grade glioma  Oligodendroglioma 
74 71 M Right temporal Metastatic tumor 
Metastatic esophageal 
adenocarcinoma 
75 62 F Right 
frontotemporal 
Glioma Glioblastoma 
76 46 F Left frontal  High-grade glioma Recurrent anaplastic 
astrocytoma  
77 39 M Left frontal High-grade glioma Glioblastoma  
78 63 F Left occipital  Metastatic tumor Metastatic breast carcinoma 
79 77 M Right temporal Metastatic carcinoma Metastatic squamous cell 
carcinoma 
80 41 F Right insular Glioma Anaplastic oligodendroglioma, 
WHO III 
81 53 F Left frontal Recurrent/residual 
high-grade glioma 
Recurrent anaplastic 
oligodendroglioma, WHO 
grade III 
51 	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82 87 M Left temporal Malignant glioma  Glioblastoma 
83 5 M Posterior fossa Glioma, favor 
pilocytic astrocytoma 
Pilocytic astrocytoma 
84 13 F Posterior fossa Glioma, favor 
pilocytic astrocytoma 
Low-grade astrocytoma  
85 55 M Left frontal Metastatic carcinoma Metastatic renal cell carcinoma 
86 43 F Left temporal  Glioma, WHO grade 
II 
Recurrent anaplastic 
astrocytoma 
87 64 M Posterior fossa Ependymoma 
Ependymoma, WHO grade II 
88 66 M Right frontal Lesional tissue  Mantle cell lymphoma 
89 56 
F 
Left temporal  Glioma Glioblastoma 
90 34 
F 
Spinal cord Ependymoma Ependymoma 
91 67 F Right frontal  
Gliotic brain tissue 
with atypical cells* Recurrent glioblastoma 
92 61 F Left frontal  Infiltrating glioma* 
Recurrent glioblastoma 
93 
74 
M Left temporal  n/a** Normal neocortex/hippocampal 
sclerosis 
94 76 M Right temporal 
lobe 
Recurrent glioma* Recurrent glioblastoma 
95 69 M Right parietal  Meningioma Meningioma 
96 12 M Right temporal 
Low-grade glioma 
Ganglioglioma 
97 24 F Left occipital Metastatic tumor Metastatic breast 
adenocarcinoma 
98 4 M Posterior fossa  Astrocytoma, favor 
pilocytic 
Pilocytic astrocytoma 
99 68 M Left parietal Glioblastoma* 
Recurrent glioblastoma 
100 1 M Posterior fossa Small round blue cell 
tumor 
Medulloblastoma  
101 15 M Posterior fossa Malignant small 
round blue cell tumor 
Malignant small round blue cell 
tumor 
101 15 M Posterior fossa Malignant small round 
blue cell 
Malignant small round blue cell 
52 	  
Note: Cases in bold (72-101) were used in the survey comparing SRH to H&E histology and as 1	  
the test set for the multilayer perceptron. 2	  
*Non-lesional tissue samples obtained at the time of frozen in these specimens were included in 3	  
the survey. The non-lesional diagnosis of specimens utilized was corroborated by SCP, a 4	  
neuropathologist. 5	  
** Comparison of the SRS image of this tissue was made to a portion of the frozen section from 6	  
case 63, which contained non-lesional tissue, as verified by SCP. 7	  
“n/a” indicates frozen section not sent. 8	  
 9	  
